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Summary: Dyslipidemia in menopause is a known feature in women, whether it leads to significant 
increase in the development of coronary heart disease (CHD) is still controversial, more so in our 
environment where little work has been done.  The present study is aimed at comparing the level of total 
serum cholesterol, including its subunits in premenopausal with that of their postmenopausal 
counterparts. This is to enable us ascertain the relative risk of developing cardiovascular disease in 
postmenopausal women in our environment.  One hundred and twenty six (126) apparently healthy, non-
pregnant females (74 premenopausal and 52 postmenopausal) were recruited for the study. Serum total 
cholesterol and their subfractions- high-density lipoproteins (HDL), low-density lipoproteins (LDL), very 
low-density lipoproteins (VLDL) and triglycerides (TG) were estimated using enzymatic and established 
mathematical methods. There was no significant difference in the total serum cholesterol and triglyceride 
between the two groups. There was however, a significant reduction of HDL and VLDL in the 
postmenopausal group (P<0.005) and a significant increase in the level of LDL in the postmenopausal 
group (P<0.005).  The elevated LDL and the reduction of cardio protective HDL and VLDL is an 








Cardiovascular disease is a leading 
cause of death among women in the developed 
world. In the United States, more than 500,000 
women die of cardiovascular disease and about 
half are due to coronary artery disease (CAD) 
(Ariyo et al, 2002). Multiple risk factors have 
been identified as contributory to the 
development of CAD. These risk factors are 
important in both men and women and are 
present in both Caucasians and Africans. They 
include cigarette smoking, hypertension, 
Diabetes mellitus and hypercholesterolemia. 
Hypercholesterolemia is a key factor in 
the pathophysiology of artherosclerosis (Igweh 
et al, 2003). Thus dyslipidemia can be 
modified by efforts aimed at cholesterol 
reduction ( Fick et al, 1987, Kane et al, 1990, 
Davidson 1993). Studies have shown that 
women are at less risk of developing CAD 
than their male counterparts, but this is 
abolished after 60 years of age (Rich-Edward 
1995 et al, Courderc et al, 1999). High levels 
of LDL and low levels of HDL are strongly 
associated with the risk of CAD ( McNamara 
et al 1992). Smaller LDL particles (LDL-III) 
are considered more atherogenic than larger 
more buoyant species because of their 
increased susceptibility to oxidation ( Dejagar 
et al, 1993) and their increased residence time 
in plasma (Rainwater, 2000). Plasma 
triglycerides concentration also has a 
determinative influence on the concentration of 
small dense LDL particles in normal 
population (Dejagar et al, 1993, Mendelsohn, 
1999). 
After menopause, there is loss of 
ovarian function. This results in adverse 
changes in glucose and insulin metabolism, 
body fat distribution, coagulation, fibrinolysis 
and vascular endothelial dysfunction (Spencer 
et al, 1977). There is also derangement of 
lipoprotein profile independent of age (Bales, 
2000). 
A number of changes that occur in the 
lipid profile after menopause are associated 
with increased cardiovascular disease risk. 
Lack of estrogen is an essential factor in this 
mechanism. Apart from maintaining friendly 
lipid profile, estrogen changes the vascular 
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tone by increasing nitrous oxide production. It 
stabilizes the endothelial cells, enhances 
antioxidant effects and alters fibrinolytic 
protein (Taddec et al, 1996). All these are 
cardioprotective mechanisms, which are lost in 
menopause. 
Dyslipidemia at menopause is not 
restricted to Caucasians. It is also evident in 
women of South Eastern Nigeria. These 
studies were aimed at determining the degree 
of dyslipidemia in the women of this region 
and relate it to the risk of developing 
cardiovascular diseases. It also attempted to 
suggest possible methods of reverting to lipid 
friendly status. 
 
Materials and Methods 
A group of 126 women, 74 premenopausal 
aged between 25-45 years and 52 
postmenopausal aged between 55-70 years 
were studied. They were of the same social 
class and selected from workers and students 
of the University of Nigeria and the University 
of Nigeria Teaching Hospital (UNTH) 
community. Some of the postmenopausal 
women were relatives of the workers. They 
were randomly selected by a lucky dip of yes 
or no after an informed consent and ethical 
clearance from the relevant ethical committee 
of UNTH Enugu was obtained. Exclusion 
criteria include obesity, pregnancy, diabetes 
mellitus, hypertension, hormonal contraception 
and heavy exercise. 
Fasting venous samples (10ml) were 
collected in heparinized bottles. This however, 
was done on the 7th day of the L.M.P. for the 
premenopausal group. Sample was centrifuged 
and plasma separated and stored in plastic 
tubes at 4oC. 
Total cholesterol was measured using 
established enzymatic methods of Allain et al 
(1974) with the Randox cholesterol kit 
(Randox England). HDL-C was isolated by 
HDL-C precipitant method (Lopes-virella et 
al, 1977). LDL was calculated with a formula 
from total cholesterol and triglycerides 
(Friedwald, 1972). Triglyceride was isolated 
enzymatically as described by Henry (1991) 
and the expert panel on detection, evaluation 
and treatment of high blood cholesterol in 
adults (Expert Panel, 1988). VLDL was 
calculated using the formula VLDL-C = 
TG/2.825mmol/L (Henry, 1991). 
Statistical analysis was done using Excel. 
Showing the mean and standard deviation. 
Comparison of mean was by student t-test. 
Permission was obtained from the Faculty 
Ethics committee to carry out this experiment. 
 
Results 
The mean, Standard deviation and the P-
values for total cholesterol, HDL-C, LDL-C 
VLDL-C and Triglycerides are shown in Table 
1. There was no significant difference in the 
total cholesterol and the triglycerides between 
the two groups (P>0.005). However there was 
significant reduction in HDL and VLDL-C 
fraction in the postmenopausal group and a 
significant increase in the value of LDL-C 
(P<0.005).  
Table 2 shows the HDL/LDL ratio 
between the two groups. Figs 1,2,3,4, and 5 
represent comparisons of means between the 
two groups. The mean age for premenopausal 
women is 36.7±4.74 and that for post 
menopausal women is 60.9±9.9 
 
Table 1: Showing Total plasma cholesterol and its subfractions in pre and    




HDL LDL VLDL TG 
Premenopausal women(n-
74) 
4.30±0.68 1.37±0.020 2.7±0.74 0.28±0.04 1.12±0.43 
Post menopausal 
women(n-56) 
4.51±0.74 1.23±0.21 3.03±0.69 0.25±0.04 1.3±0.73 
P.Values 0.117 0.005 0.039 0.004 0.137 
Significance P>0.05 P<0.05 P<0.05 P<0.05 P>0.05 
 
Table 2: HDL/LDL Ratio in pre and postmenopausal women 
 




1.37 2.7 1:2 
Post menopausal 
women 
1.23 3.03 1:3 














































































































































Fig. 1: Mean Serum Cholesterol ( Pre and post menopausal)
Fig. II: Mean HDL-C ( Pre and post menopausal) 
Fig III: Mean LDL-C ( Pre and post menopausal)
Fig IV: Mean VLDL-C ( Pre and post menopausal) 
Fig. V: Mean TG ( Pre and post menopausal)




There are variations in lipid levels 
obtained in different individuals based on race, 
age, sex, obesity, exercise, smoking, alcohol, 
diet, diseases like hypertension, chronic liver 
and renal diseases (Gordon et al, 1987, Jarikre 
et al, 2000). However, in this study we tried to 
exclude the co founding variables and results 
obtained can be taken as the standard normal 
in our environment. The premenopausal values 
are similar to values obtained in other studies 
in different parts of the country (Ajose et al, 
2002, Igweh et al, 2003). 
However, there is paucity of literature in 
postmenopausal values in Nigeria, but studies 
on total cholesterol alone done in Ibadan 
showed no significant change ( Otolorin et al, 
1989), as was the case in our study. 
Studies in some centers in developed 
countries showed higher values with 
dyslipidemia being taken as cholesterol > 
240mg% (6.21mmol/l) and occurs in 25-33% 
of women (Grundy, 1994, Gordon et al, 1989). 
As a result of racial, genetic and technical 
differences, it has been suggested that our own 
cut off level should be adjusted to suit our 
peculiar circumstances. In determining the risk 
of cardiovascular disease, the absolute 
cholesterol value is not the most important 
factor; rather the concentrations of the various 
subclasses of cholesterol. In the present study 
there was no significant differences in the total 
cholesterol level but there was significant 
reduction in the cardio protective HDL-C and 
VLDL-C and significant increase in the 
artherosclerotic LDL-C. This is in agreement 
with findings in other studies ( Jenson et al, 
1990, Edr et al, 1982, Igweh et al, 2003). It has 
also been estimated that for any 1mg/dl 
(0.026mmol/ml) increase in HDL-C, there is a 
3% decrease in risk of coronary artery disease 
and a 4.7% decrease in the risk of mortality 
from cardiovascular disease (Okonofua 1990). 
In this study this protective effect was lost by 
five fold. Again the HDL/LDL ratio was 
increased in the post menopausal group and it 
has been shown that HDL/LDL ratio is a 
significant predictor for the development of 
artherosclerosis both in Caucasians and 
Nigerians (Aina 1992, Park et al, 2000). 
There is no doubt from this study that the 
changes that occur in the lipid profile after 
menopause is not friendly for the 
cardiovascular health of our women. It is 
generally believed that postmenopausal 
symptoms are less in our women than their 
Caucasian counterparts. This may not be true 
because several studies in the past have shown 
psychological, physical, biochemical, 
hormonal and vasomotor parameters that are 
not of great variance with what is obtained else 
where (Grundy, 1994, Mandel et al, 2002, 
Pirway et al, 2002). The problem is that the 
harsh climatic and poor socioeconomic 
environment overwhelms our women that they 
hardly ever complain about menopausal 
symptoms unless it is severe. 
The elevated LDL and the reduction in the 
cardio protective HDL and VLDL is an 
indication that menopause is an independent 
risk factor for developing cardiovascular 
disease in our environment. 
Several studies have shown the beneficial 
effects of hormonal replacement therapy on the 
lipid profile of menopausal women (Abbot et 
al, 1988, Stampfer et al, 1991, Stampfer, 
1991). However, controversy exists as to 
whether these changes culminate to reduced 
risk of cardiovascular heart disease. 
Observational studies over the years have 
touted the beneficial effects of hormone 
replacement therapy (HRT) in preventing 
coronary heart disease in post menopausal 
women (Hulley et al, 1998). More recent 
studies have however, cast some doubts on the 
beneficial effects of HRT especially in patients 
with established cardiovascular disease 
(Cheng, 2000). Further studies are needed in 
this area. 
It should be noted that our post 
menopausal women have unfriendly lipid 
profile; it is thus important to note this and 
device means of correcting the dyslipidemia 
since the use of HRT and lipid lowering drug 
is still controversial. It is important to counsel 
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